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The ability to directly monitor the status of the placenta throughout pregnancy would be a major
advance in both general and personalized obstetric care, allowing treatments to be tailored to the dy-
namic changes that can occur in gestation. Syncytiotrophoblast extracellular vesicles (STBEV) are
membrane bound vesicles, released from the surface of the placenta directly into the maternal circu-
lation, in the form of exosomes, microvesicles and apoptotic bodies. They carry many syncytiotrophoblast
derived factors such as proteins, lipids, glycans and nucleic acids, which together could dynamically
signal to the mother the status of the placenta. We review STBEV research and discuss the potential for
STBEV to be used as circulating syncytiotrophoblast biopsies, accessible via a simple blood sample
throughout pregnancy, giving a real-time readout of syncytiotrophoblast health. We also highlight ad-
vances in the use of extracellular vesicles as circulating tumour derived biopsies in the ﬁeld of cancer
research, which could prove beneﬁcial to obstetric care.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The syncytiotrophoblast (STB) is fundamental to the establish-
ment andmaintenance of a healthy pregnancy. Therefore, impaired
functional capacity of the STB impacts directly on fetal develop-
ment and maternal adaptations to pregnancy. An extreme example
is preeclampsia (PE) where the only effective treatment is removal
of the placenta [1]. Acute or chronic changes that occur through
physiological or pathological mechanisms can lead to impaired STB
function. Such changes will probably vary within one placenta and
between individual pregnancies, although certain pathological
processes may be common to speciﬁc complications [2]. A real time
read out of STB functional status, accessible throughout gestation,
would be invaluable in monitoring STB performance and permit
direct measurement of placental health.
Extracellular vesicles (EV) are membrane bound, cell derived
particles released by many different cell types. The term EV en-
compasses exosomes (~100 nm in diameter), microvesicles
(0.1e1 mm) and apoptotic bodies (0.5e5 mm), released as part of
both normal physiological functions, such as haemostatictritional Sciences, University
AP, UK.
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ogies, such as cancer, cardiovascular disease and inﬂammatory
disorders [3e5]. Cellular responses such as activation, stress and
death alter the molecular ﬁngerprint of the EV cargo, making them
potential biopsies of inaccessible tissues and allowing measure-
ment of multiple biomarkers derived from a speciﬁc source [6]. STB
releases EV (STBEV), containing a complex cargo of RNAs, proteins,
glycans and lipids, from the apical surface directly into thematernal
circulation in normal pregnancy and PE, fuelling interest in their
use as biomarkers of placental wellbeing [7e12].2. Types of STBEV and their role in normal pregnancy and PE
The STB layer releases exosomes, microvesicles and apoptotic
bodies that pass through thematernal pulmonary capillary bed and
out into the systemic circulation [7]. In normal pregnancy, some, if
not all of the STBEV subtypes are released constitutively and are
thought to have a role in inducing maternal adaptive changes,
which include suppressed maternal cell mediated immunity [13].
Possible immunoregulatory factors carried by STBEV include
apoptosis inducers FasL and TRAIL, the NKG2D receptor modulators
MIC A/B and ULBPs and the T cell regulators B7-H1, B7-H3 and HLA-
G5 [14e16]. Interestingly, changes in STBEV immunoregulatory
activity have also been seen over the course of normal pregnancy,
with ﬁrst trimester STBEV beingmore pro-inﬂammatory than thoseunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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potential physiological changes in STBEV phenotype and cargo over
the course of gestation although, since ﬁrst trimester placental
tissue is obtained after pregnancy termination, artefactual stresses
could have a signiﬁcant impact on the observed changes in STBEV
biological activity.
The placenta plays a key role in triggering systemic inﬂamma-
tion, endothelial dysfunction and hypercoagulation that underlie
the maternal symptoms of PE. The maladaptations underpinning
severe disease occur early in pregnancy, with inadequate remod-
elling of the uteroplacental spiral arteries leading to compromised
placental perfusion [18,19]. Impaired placental function may ensue
and, in severe cases, damage due to inﬂammatory, oxidative and ER
stresses occurs, all of which could stimulate the release of excess
STBEV with a pathological phenotype and cargo [20,21]. This sce-
nario is supported by several studies, including our own work
showing that treatment of BeWo choriocarcinoma cells with tuni-
camycin, to induce ER stress, stimulates the increased release of EV,
larger in size and carrying an increased cargo of danger associated
molecular pattern (DAMP) molecules (G Collett unpublished
observation), also known as alarmins, which are key players in
triggering a sterile inﬂammatory response [22]. Using STBEV pre-
pared from ex vivo placental lobe dual perfusion and cultured term
placental explants, STBEV released by PE placentas (PE-STBEV)
were also found to be signiﬁcantly larger than those from normal
placentas [17,21]. In vitro, PE-STBEV differentially affect immune
cell, endothelial cell and platelet activation, suggesting a role in the
maternal systemic inﬂammatory response, endothelial dysfunction
and hypercoagulation, which are part of the maternal syndrome of
PE [17,23e25]. In summary, the spectrum of STBEV subtypes
released in PE, changes from smaller exosomes towards larger
microvesicles and apoptotic bodies, which carry an altered reper-
toire of biologically active factors, consistent with increased
placental stress in PE. However, the biological effects of STBEV
isolated from placentas of normal, early onset PE and late onset PE
pregnancies have not been systematically compared, which would
add much to our understanding of the underlying placental
pathology.
3. Circulating STBEV in normal pregnancy and PE
Circulating levels of EV reﬂect the balance between the rates of
release and clearance. In animal models EV are rapidly cleared from
the circulation, predominantly by liver and spleen, suggesting that
a signiﬁcant increase in EV release (or decrease in clearance rate)
would be required to impact circulating levels [26,27]. STBEV are
taken up by circulating monocytes, B cells and platelets [25,28], but
no data are available on clearance of STBEV by organs (e.g. lungs,
heart, kidneys, liver and spleen). It is also not known whether
STBEV leave the circulation via interstitial ﬂuid into the lymphatic
system or to what extent circulating STBEV represent the popula-
tion ﬁrst released by the placenta. This highlights the need for
comparisons between STBEV originally released by the STB (e.g.
ex vivo derived STBEV from placental dual perfusion or those pre-
sent in uterine vein blood samples, which would most closely
reﬂect the total STBEV population) and peripheral circulating
STBEV.
In normal pregnancy, circulating STBEV are detectable in the
ﬁrst trimester by both placental alkaline phosphatase (PLAP; STB
marker) immunoassay and ﬂow cytometry (both free and bound to
monocytes), with levels progressively rising over the course of
gestation and peaking at term [29]. In established PE, circulating
STBEV levels are signiﬁcantly higher in early onset PE (<34 weeks)
compared to matched normal pregnancy [29,30]. However, it is not
known if increased STBEV levels also predate clinical symptoms ofPlease cite this article in press as: D. Tannetta, et al., Syncytiotrophoblast e
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nancy and PE is also not available owing to a lack of reliable subtype
speciﬁcmarkers. Circulating levels of EV that are double positive for
PLAP and CD63 (marker enriched in exosomes) were reported to be
detectable at 6 weeks and to rise over the subsequent course of
normal gestation, suggesting that STB derived exosomes can reach
the systemic circulation prior to the establishment of blood ﬂow
into the intervillous space (~10 weeks gestation), although the
mechanism enabling this transfer is not known [31,32].
Quantiﬁcation of circulating STBEV number is dependent on the
sensitivity of the method used. In theory immunoassays using PLAP
for capture and/or substrate cleavage should give a measure of the
total PLAP positive STBEV population. This assumes that any dif-
ferences in comparisons are due to changes in STBEV number
rather than PLAP expression. Using nanoparticle tracking analysis
(NTA) and ﬂuorescence-NTA; techniques able to track individual EV
in the size range of 50 nm to 1 mm, we found lower PLAP positivity
in placental perfusate derived exosomes compared to preparations
enriched for microvesicles, suggesting lower PLAP expression on
STB derived exosomes [33]. This may be due to the smaller surface
area of exosomes compared tomicrovesicles, or selective packaging
of PLAP into microvesicles. We have also found PLAP expression to
be signiﬁcantly lower for PE-STBEV, compared to those derived
from healthy pregnancy placentas, using mass spectrometry
(measures total (surface and intravesicular) PLAP; D Tannetta un-
published observation), Western blotting (total PLAP) and ﬂow
cytometry (surface PLAP), suggesting that PLAP positivity may give
an underestimate of STBEV number in PE [21]. By ﬂow cytometry,
which has an EV detection limit of 300e500 nm (favouring
detection of microvesicles and apoptotic bodies), PLAP positive
STBEV have been estimated to comprise ~0.5e5% of the total EV
population [34,35]. Finally, the total number of plasma exosomes,
isolated using density gradient ultracentrifugation and quantiﬁed
by NTA, has been estimated to increase 50 fold in the ﬁrst trimester
of pregnancy, although the contribution of placenta derived exo-
somes to this increase is currently not known [31]. Therefore,
although there is strong evidence that STBEV can be found in the
maternal circulation from 6 weeks onwards, quantiﬁcation of their
absolute number, given these ﬁndings, remains challenging.
4. STBEV as STB biopsies
STBEV have promising attributes for being effective STB bi-
opsies. They are released directly into the maternal circulation, so
minimal invasive sampling is required. In theory, circulating STBEV
are derived from the entire surface of the placenta; therefore, un-
like a traditional biopsy which involves small tissue sampling areas,
circulating STBEV would give a much better overall representation
of STB status. STBEV also express STB speciﬁc surface markers such
as PLAP that enable their exclusive isolation [21]. STBEV carry a
varied cargo derived directly from the STB, but their intravesicular
cargo is also protected by a phospholipid bilayer that could help to
improve detection of low abundance biomarkers and those with a
short half-life, such as mRNAs [36]. Given their rapid clearance it is
likely that they represent an up-to-date picture of current STB
health [26,27,37]. Also, longitudinal studies measuring circulating
levels of STB derived exosomes, microvesicles and apoptotic bodies,
would not only reveal the dynamics of STBEV subtype release but
give a non-invasive analysis of STB turnover, and how it changes
under stress conditions. Finally, if STBEV release and cargo can
reﬂect pathological changes, STBEV have great potential as bio-
markers for personalized diagnostics, allowing the tailoring of
treatments to a particular patient's circumstances. This could prove
to be important for the effective treatment of heterogeneous syn-
dromes such as PE.xtracellular vesicles e Circulating biopsies reﬂecting placental health,
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Fig. 1. Schematic diagram summarising current literature on circulating levels of syncytiotrophoblast derived extracellular vesicles (STBEV) in normal pregnancy and preeclampsia.
The intensity of the shading represents the incidence of pathological changes in the placenta and when corresponding changes in STBEV composition may be most evident.
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markers to discriminate STBEV subtypes. So it is not known
whether a speciﬁc STBEV subtype or the total STBEV population
would be a better circulating STB biopsy. The study of ex vivo
placenta derived preparations of STBEV has important limitations,
especially with early onset PE requiring preterm delivery. Normal
preterm controls are not readily available so differences may reﬂect
gestational age rather than pathology. By necessity, such in-
vestigations use placental material collected when the disease is
established, but predictive biomarkers should be present prior to
clinical symptoms (Fig. 1). The study of blood derived STBEV would
allow both retrospective matching of normal pregnancy and PE
samples and analysis of STBEV biomarker potential prior to onset of
disease. However, current variation in the methods used to collect
samples and isolate and characterise STBEV could all impact on
STBEV composition. Without standard procedures, this makes the
validation of results across laboratories much harder.5. Isolation of circulating STBEV
Ideally, an effectivemethod for the isolation of circulating STBEV
would require routine blood handling techniques, minimal sample
preparation and would give a high yield of undamaged pure STBEV
from a small sample volume. In reality, the targeted isolation of
phenotypical EV from a blood sample requires specialised isolation
and detection methods, due to the subcellular nature of EV and the
complexity of blood which, apart from cells, also contains EV from
multiple sources (including platelets, red blood cells, leucocytes
and endothelial cells) as well as numerous soluble factors with the
potential to interfere in isolation methods and downstream ana-
lyses (such as STBEV cargo determination using transcriptomic and
proteomic approaches). However, prior to isolation, venepuncture
and blood handling, type of anticoagulant and fasting status are just
some of the pre analytical variables that can affect the EV compo-
sition of a sample [38]. Multiple processing steps can also lead to
accumulating losses of EV. Therefore, to minimalize the impact of
such losses, the level of purity required for any subsequent analyses
should be taken into account when choosing an appropriate
isolation technique [6,39].
Crude preparations of total EV can be quickly obtained by pre-
cipitation techniques followed by low speed centrifugation [40].Please cite this article in press as: D. Tannetta, et al., Syncytiotrophoblast e
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density, such as differential centrifugation, density gradient ultra-
centrifugation, microﬁltration and size exclusion chromatography
[40,41]. For even greater purity and enrichment of particular EV
phenotypes, immunocapture using antibodies to speciﬁc surface
antigens has also proved effective [42]. There are advantages and
disadvantages to each method that have been comprehensively
reviewed [6,42e44]. Brieﬂy, centrifugation techniques have been
widely used to isolate EV from various sample types and have also
been used to fractionate EV into microvesicles and exosomes, such
as STBEV from placental perfusate and dendritic cell EV [33,45].
However, EV isolated using techniques such as precipitation and
ultracentrifugation can be contaminated with protein aggregates
and, in the case of blood derived samples such as plasma, high
density lipoproteins, which can interfere in downstream analyses
[43,46]. Size exclusion chromatography (SEC) is becoming the
preferred method for EV isolation because it is a quick and gentle
method that gives high yields of EV with good separation from
soluble proteins [41]. However, for rapid diagnostic use, highly
enriched EV of a particular phenotype can be obtained using
microﬂuidic devices and immunocapture onto beads, magnetic
nanoparticles or chips by targeting those EV expressing particular
surface markers [42].
PLAP has proved to be a very useful marker for STB derived EV
detection, however during pregnancy soluble PLAP circulates at
high levels and could compete with STBEV bound PLAP for
immunocapture. Also, as described above, STBEV associated PLAP is
signiﬁcantly reduced in PE [21]. Therefore, although PLAP is a
robust STBEV marker, its use to determine STBEV number may lead
to an underestimation in PE. Partially enriched preparations of
STBEV could also be obtained by using a marker expressed on
STBEV and EV of other cell types affected in PE such as endoglin;
expressed on STBEV in normal pregnancy and PE and also carried
by endothelial cell derived EV, the circulating levels of which are
increased in PE [21,47,48]. As the STB is the largest epithelium in
direct contact with maternal blood during pregnancy, an alterna-
tive strategy could be to isolate epithelial derived EV. The onco-
protein mucin-1 is a transmembrane glycoprotein highly expressed
on the apical surface of polarised epithelia, including STB where
expression of mucin-1 is signiﬁcantly increased in PE [49]. Mucin-1
is also expressed on the surface of EV released by several tumourxtracellular vesiclese Circulating biopsies reﬂecting placental health,
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contain mucin-1 at signiﬁcantly increased levels in PE, showing
promise as a circulating STBEVmarker in PE (D Tannetta, R Dragovic
& G Collett unpublished observation).
6. Parallels with cancer EV
Cancer cells also release EV that are implicated in tumour pro-
gression and metastasis such as inﬂammation, modulation of cell
mediated immunity and angiogenesis [53,54]. Here, biomarkers in
personalized care cover multiple stages in the development and
treatment of cancer including screening, early diagnosis, predic-
tion, prognosis and monitoring disease progression [54]. Indeed,
cancer displays all the problems of heterogeneity both between and
within patients and the need for a personalized approach to
treatment, which are likely operative in PE.
The cancer ﬁeld leads the way in the clinical application of EV
analysis, in particular of exosomes, and in the use of exosome
derivedmRNA, miRNA and protein based assays [44,54]. Traditional
methods of isolating exosomes, such as differential centrifugation,
are not suitable for routine clinical application owing to low sample
throughput and low exosome yield and purity. The need for highly
sensitive and speciﬁc detection systems due to the relatively low
abundance of tumour speciﬁc exosomes in a heterogeneous mix of
circulating EV also poses a challenge, analogous with the detection
of circulating STBEV during early pregnancy.
Novel techniques for the capture and analysis of cancer derived
EV have and continue to be developed. This includes methods such
as on-chip immunoelectrophoresis, which identiﬁes changes in the
zeta potential of individual cancer EV following binding of EV
speciﬁc antibodies [55]. Nanoplasmonic technology has been uti-
lised to capture ovarian cancer exosomes using epithelial marker
speciﬁc antibodies [56]. An acoustic nanoﬁlter system has also been
developed that separates EV according to size and density using
differential acoustic force generated by ultrasound waves [57].
Finally, serum colorectal cancer derived EV have been detected
directly in patient blood samples using Exoscreen, a technique
whereby cancer speciﬁc EV are captured using two types of anti-
bodies and detected by photosensitizer beads [58]. Interestingly,
identiﬁcation of novel disease biomarkers may not be necessary as
exosome association may also improve existing biomarker speci-
ﬁcity. For example, exosome associated levels of the validated
prostate cancer biomarker prostate-speciﬁc antigen (PSA), have
been found to have higher disease speciﬁcity than total circulating
and urinary levels [59,60]. Likewise, given the controversy over the
variability in reported levels and cellular source of circulating sFlt-1
in PE, STBEV associated sFlt-1 could be a more informative measure
of placenta derived sFlt-1 [61]. Such innovations may aid the
pregnancy ﬁeld to overcome limitations such as low numbers of
circulating STBEV during early pregnancy and speciﬁcity of some
circulating PE markers, enabling better utilisation of STBEV for
clinical applications.
7. Conclusions
There is increasing evidence that STBEV have huge potential as
circulating STB biopsies, easily accessible throughout gestation and
as a real time reﬂection of STB status. Their complex cargo of mRNA,
miRNA, proteins, glycans and lipids gives a potentially rich source
of biomarkers in complications involving placental dysfunction.
Most focus has been on STBEV as biomarkers to predict or diagnose
PE, with the cargo giving a PE ‘ﬁnger print’ reﬂecting speciﬁc
pathological mechanisms such as inﬂammatory, oxidative and ER
stresses. However, there is now a pressing need to relate data on
STBEV and their cargo, generated ex vivo from normal and PEPlease cite this article in press as: D. Tannetta, et al., Syncytiotrophoblast e
Placenta (2016), http://dx.doi.org/10.1016/j.placenta.2016.11.008affected placentas to STBEV found in blood samples. Moreover, a
thorough proﬁling of circulating STBEV during the course of normal
pregnancy is also needed to facilitate the identiﬁcation of patho-
logical changes. This would be greatly beneﬁtted by the develop-
ment of an efﬁcient, reliable and clinically feasible extraction
method. Finally, STBEV show promise in the clinical monitoring of
PE, but STBEV analysis may also be applicable to other forms of
placental compromise/stress and even epigenetic changes that may
alter both short and long term fetal outcomes.
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